FDA Brief

Warning letters Drugs

FDA warning letter to

Je Dois Lavoir LLC

High riskIssued Aug 11, 2021Posted Aug 24, 2021Division of Pharmaceutical Quality Operations IV

Je Dois Lavoir sells 365 Skinny High Intensity weight-loss drug containing undeclared sibutramine without FDA approval.

What happened

FDA reviewed the company's website in June 2021 and social media pages, which directed consumers to the website to buy "365 Skinny High Intensity." Laboratory analysis confirmed the product contained undeclared sibutramine, the active ingredient in the withdrawn prescription drug Meridia, which FDA says increases heart attack and stroke risk. The firm voluntarily recalled 365 Skinny High Intensity and 365 Skinny Emergency Boutique on August 2, 2021.

What FDA found

  1. The company sold 365 Skinny High Intensity as a weight-loss drug without the FDA-approved application required for a new drug.

    FD&C Act §§ 505(a), 301(d), 21 U.S.C. 355(a), 331(d)
  2. The product was marketed as a dietary supplement but contains sibutramine, a drug ingredient that is excluded from the dietary supplement definition.

    FD&C Act § 201(ff)(3)(B)(ii), 21 U.S.C. 321(ff)(3)(B)(ii)
  3. The product's labeling does not give adequate directions for safe use by a layperson.

    FD&C Act § 502(f)(1), 21 U.S.C. 352(f)(1); 21 CFR 201.5
  4. The labeling is false or misleading because it does not reveal that the product contains sibutramine.

    FD&C Act §§ 502(a), 201(n), 21 U.S.C. 352(a), 321(n)
  5. The labeling lacks adequate warnings to protect users.

    FD&C Act § 502(f)(2), 21 U.S.C. 352(f)(2)
  6. The product is dangerous to health when used as labeled because sibutramine raises heart attack and stroke risk.

    FD&C Act § 502(j), 21 U.S.C. 352(j)

What FDA wants

FDA asks the company to notify it in writing within 15 working days of the steps taken to address the violations, including an explanation of each step and related documentation. If corrective actions cannot be completed in that time, the company must state the reason for delay and when it will finish.

Who should pay attention

  • consumers buying weight-loss supplements online
  • retailers and online marketplaces selling "365 Skinny" products
  • quality teams checking weight-loss supplements for undeclared drug ingredients

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  2. Jing Cheong Asia Inc. dba New York Tong Ren Tang

    New York Tong Ren Tang marketed unapproved new drugs, including eye drops, on its website.

    High risk
  3. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk
  4. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk